Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Core Insights - Disc Medicine, Inc. is set to present initial data from the RALLY-MF Phase 2 trial of DISC-0974 for anemia of myelofibrosis at the ASH Annual Meeting in December 2025 [1][2] - The company aims to provide updates on the trial results, including data from a broader patient population and the drug's efficacy as a monotherapy and in combination with JAK inhibitors [2] - Additionally, a poster on the ongoing Phase 2 trial of DISC-3405 in polycythemia vera will be presented, with initial readouts expected in 2026 [2] Presentation Details - The DISC-0974 poster presentation is scheduled for December 6, 2025, from 5:30 pm to 7:30 pm EST, with Naseema Gangat as the presenting author [4] - The DISC-3405 poster presentation will also occur on December 6, 2025, during the same time frame, presented by Marcus Carden [5] Company Overview - Disc Medicine is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious hematologic diseases, targeting key biological pathways related to red blood cell biology [6]